

EMA/501874/2008

European Medicines Agency decision

P/0240/2020

of 19 June 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rozanolixizumab (EMEA-002681-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0240/2020

of 19 June 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for rozanolixizumab (EMA-002681-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by UCB Pharma S.A. on 12 August 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 May 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for rozanolixizumab, solution for infusion, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for rozanolixizumab, solution for infusion, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for rozanolixizumab, solution for infusion, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to UCB Pharma S.A., Allée de la Recherche, 60, 1070 – Brussels, Belgium.

EMA/PDCO/129370/2020
Amsterdam, 29 May 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002681-PIP01-19

Scope of the application

Active substance(s):

Rozanolixizumab

Condition(s):

Treatment of myasthenia gravis

Pharmaceutical form(s):

Solution for infusion

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

UCB Pharma S.A.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, UCB Pharma S.A. submitted for agreement to the European Medicines Agency on 12 August 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 17 September 2019.

Supplementary information was provided by the applicant on 21 February 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of myasthenia gravis

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for infusion, subcutaneous use;
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric investigation plan

2.1. Condition:

Treatment of myasthenia gravis

2.1.1. Indication(s) targeted by the PIP

Treatment of myasthenia gravis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	1	Study 1 Open-label, single arm activity, safety and pharmacokinetic study of rozanolixizumab in paediatric patients from 2 to less than 18 years of age with generalised myasthenia gravis (gMG) with moderate to severe symptoms.
Extrapolation, modelling and simulation	1	Study 2 Development of an exposure response model to support the dose

studies		selection of rozanolixizumab for Study 1 and confirmation of final paediatric recommended dose.
Other studies	1	Study 3 Systematic review of literature to map existing evidence on the effect of age, maturation, disease type, severity, comorbidity for myasthenia gravis, supporting extrapolation of efficacy data from adults to paediatric patients.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes